PDS Biotechnology Income Tax Expense Over Time

PDSB Stock  USD 1.20  0.03  2.44%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PDS Biotechnology Performance and PDS Biotechnology Correlation.
  
As of March 10, 2025, Income Tax Expense is expected to decline to about (1.3 M).
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Return On Assets
(0.45)
Return On Equity
(1.74)
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Income Tax Expense Analysis

Compare PDS Biotechnology Corp and related stocks such as Mereo BioPharma Group, Terns Pharmaceuticals, and Inozyme Pharma Income Tax Expense Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
MREO(1.1 M)(1.1 M)(1.1 M)(1.1 M)(1.1 M)(1.1 M)(5.3 M)(8.2 M)(5.3 M)(6.3 M)(2.8 M)1.5 M(1.9 M)(532 K)(611.8 K)(642.4 K)
TERN(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(20 K)813 K508 K358 K239 K274.9 K335.7 K
INZY4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M(1.1 M)(587 K)(211 K)(1.6 M)(1.6 M)(1.5 M)(1.4 M)
HOOKKKKKKKKK24 K(8.9 M)(10.3 M)1000230 K368 K106 K111.3 K
ENVB100 KK1.9 K1.4 K833(128.5 K)(3.7 M)(2.4 M)6.3 M388.7 K(477.7 K)(7.5 M)(1.5 M)28.9 K26 K27.3 K
OCEA(171.9 K)(171.9 K)(171.9 K)(171.9 K)(171.9 K)(171.9 K)(171.9 K)(171.9 K)(171.9 K)(171.9 K)1000(1000)(1.5 M)(1.5 M)(1.4 M)(1.3 M)
XFOR395 K395 K395 K395 K395 K395 K2.6 M1.9 M3.9 M3.8 M148 K17 K28 K78 K70.2 K66.7 K
DAWN(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(3.3 M)(2.3 M)(10 M)(7.1 M)(6.4 M)(6.8 M)
ELEV(8.8 K)(8.8 K)(8.8 K)(8.8 K)(8.8 K)(8.8 K)(8.8 K)(8.8 K)(8.8 K)(8.8 K)(191.3 K)(218.6 K)25 K30 K43 K45.1 K

PDS Biotechnology Corp and related stocks such as Mereo BioPharma Group, Terns Pharmaceuticals, and Inozyme Pharma Income Tax Expense description

My Equities

My Current Equities and Potential Positions

PDS Biotechnology Corp
PDSB
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationNew Jersey; U.S.A
ExchangeNASDAQ Exchange
USD 1.2
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
Check out PDS Biotechnology Performance and PDS Biotechnology Correlation.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
PDS Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of PDS Biotechnology technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of PDS Biotechnology trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...